IMVEXXY Drug Patent Profile

Which patents cover Imvexxy, and what generic alternatives are available?

Imvexxy is a drug marketed by Mayne Pharma and is included in one NDA. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-five patent family members in twenty-one countries.

The generic ingredient in IMVEXXY is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Imvexxy

A generic version of IMVEXXY was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for IMVEXXY

International Patents:	165
US Patents:	20
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	2
Drug Prices:	Drug price information for IMVEXXY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMVEXXY
What excipients (inactive ingredients) are in IMVEXXY?	IMVEXXY excipients list
DailyMed Link:	IMVEXXY at DailyMed

See drug prices for IMVEXXY

Recent Clinical Trials for IMVEXXY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Teva Pharmaceuticals USA	Phase 3
University Hospitals Cleveland Medical Center	Phase 4

See all IMVEXXY clinical trials

Paragraph IV (Patent) Challenges for IMVEXXY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMVEXXY	Vaginal Inserts	estradiol	4 mcg and 10 mcg	208564	1	2019-12-30

US Patents and Regulatory Information for IMVEXXY

IMVEXXY is protected by thirty-four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes

International Patents for IMVEXXY

See the table below for patents covering IMVEXXY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	095619	FORMULACIÓN Y TERAPIAS PARA SUSTITUCIÓN HORMONAL DE COMBINACIÓN NATURAL
Argentina	098160	COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS EN LA VAGINA Y PROCEDIMIENTOS
Argentina	099872	FORMULACIONES DE PROGESTERONA
Argentina	107022	COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS POR VÍA VAGINAL Y MÉTODOS
Argentina	127914	COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS EN LA VAGINA Y PROCEDIMIENTOS

Supplementary Protection Certificates for IMVEXXY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	C00136011/03	Switzerland		PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0584952	99C0004	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310

IMVEXXY (estradiol vaginal inserts) market dynamics and financial trajectory: pricing, uptake, payer coverage, and exclusivity-driven competitive risk

Last updated: July 21, 2026

IMVEXXY (estradiol vaginal insert, 4 mcg and 10 mcg) is a niche, brand-priced women’s health product. Its near-term financial trajectory is determined by (1) the size and growth of the genitourinary syndrome of menopause (GSM) treated population, (2) formulary access by major pharmacy benefit managers for low-dose local estrogen, and (3) competitive pressure from generic estradiol vaginal tablets/inserts and alternative branded local estrogen products. Patent and exclusivity timing drive the inflection points for generic and “authorized pathway” competitive entries.

What is IMVEXXY and how is it positioned commercially in GSM?

IMVEXXY is marketed for treatment of moderate to severe dyspareunia due to menopause. The product is a local estrogen therapy delivered via vaginal inserts with low systemic exposure versus older oral or transdermal alternatives, which supports payer acceptance when aligned to formulary criteria for GSM.

Key commercial positioning levers

• Disease focus: GSM/dyspareunia indications, typically managed with step therapy across nonhormonal, then local estrogen.
• Delivery: low-dose vaginal inserts in two strengths (commonly referenced as 4 mcg and 10 mcg) for titration-style coverage and prescribing convenience.
• Competitive set: local vaginal estrogen products including estradiol tablets (generic and branded), estradiol vaginal rings, conjugated estrogen vaginal creams, and other branded insert/tablet formats.

How do pricing and reimbursement dynamics affect IMVEXXY net sales?

IMVEXXY’s financial trajectory is driven by the gap between list price and net price after rebates, wholesaler terms, and payer discounts. Local estrogen products are frequently competed on net price because payers can steer to lower-cost estradiol generics or therapeutically equivalent local alternatives.

Payer and PBM dynamics that typically move net price

• Preferred status in women’s health formularies
• Coverage criteria tied to “GSM/dyspareunia” and menopausal status
• Step edits that route prescribers to lower-cost estradiol vaginal generics first
• Contracting outcomes with large PBMs (rebate leverage vs preferred alternatives)

What to watch in financial reporting

• Gross to net compression versus local estrogen peers
• Mix shift between 4 mcg and 10 mcg if reimbursement favors one strength
• Channel inventory: normalized wholesaler demand versus pull-through at retail

What is the competitive landscape for IMVEXXY, and where does it lose or win?

IMVEXXY’s competitive pressure is concentrated in local estradiol products because payers treat them as close therapeutic substitutes for GSM dyspareunia.

Competitive substitutes (segment-level)

• Estradiol vaginal tablets (including generic entries)
• Estradiol vaginal rings (lower frequency dosing can change patient preference)
• Vaginal estrogen creams (often discounted via generic availability)
• Other marketed local estrogen inserts or branded products, depending on regional availability

Advantage pathways for IMVEXXY

• If formulary teams recognize the insert’s adherence profile or perceived tolerability
• If prescribers treat IMVEXXY as a “patient preference” product after failure or intolerance to creams/tablets
• If pharmacy benefit coverage avoids mandatory switching

Where IMVEXXY is exposed

• Broad formulary access for generics that can undercut net price
• Any movement from preferred to non-preferred tier placement
• Substitution at pharmacy for therapeutically equivalent estradiol formulations

When does IMVEXXY lose exclusivity, and what are the key patent and regulatory drivers?

IMVEXXY’s generics risk hinges on FDA regulatory milestones and the exclusivity/patent regime tied to its approved NDA/BLA (IMVEXXY is an NDA). Exclusivity typically includes:

• Market exclusivity (for new chemical entity or new formulation)
• Patent-protected exclusivity and listed Orange Book patents
• Potential for ANDA 3-paragraph/paragraph IV filings to launch after patent expiry or court outcomes

Patent estate mechanics that control generic entry

Generic entry risk is a function of:

• Orange Book listed composition, formulation, and method-of-use patents
• Remaining patent life (expiry/expiration dates)
• Likelihood of successful Paragraph IV challenges and settlement-driven “carve-out” launch dates
• Exclusivity stacking (if any) that extends nonmarketing periods beyond patent expiry

Practical generic entry scenarios that shape revenue

• At-expiry launches: generic entry on the first date after the last blocking patent expires
• “First-to-file” precedents: earlier ANDA filing can capture shared exclusivity if statutory conditions are met
• Settlement terms: branded company may pay to delay launch or agree to design-around labeling restrictions

What is the Orange Book status of IMVEXXY and what patents are listed?

The Orange Book listing set determines which patents block generic approval and controls Paragraph IV opportunities. IMVEXXY’s financial trajectory is directly tied to whether the listed patents are:

• Strong and widely asserted (composition/formulation and method-of-use)
• Narrow (easy to design around)
• Near expiration (creating a predictable launch window for ANDA challengers)

What drives “Orange Book” impact on revenue

• Number of listed patents in each expiry “cluster”
• Whether claims cover critical product characteristics (insert composition, release profile, or manufacturing)
• Whether method-of-use patents tie exclusivity to a specific dosing/indication or administration method

How many patents cover IMVEXXY formulations and administration, and how strong is the patent estate?

Financial impact correlates with patent breadth and enforceability. For local estrogen products delivered as inserts, the highest commercial sensitivity is in patents that cover:

• Composition of estradiol insert formulations
• Excipients and dose form characteristics
• Manufacturing process conditions that are hard to replicate
• Method-of-use claims that are tied to patient subgroups or dosing regimens

Patent strength indicators used in licensing and litigation decisions

• Claim scope (product-by-process vs strict structural claims)
• Prior art overlap (validity risk)
• Obviousness and enablement exposure
• Injunction likelihood and litigation duration (delays increase brand sales)

What patent litigation affects IMVEXXY, including Paragraph IV outcomes and settlements?

IMVEXXY’s revenue curve can show sharp inflections following:

• Court decisions on ANDA/PIV claims
• Settlement agreements setting delayed launch dates
• Design-around approvals enabling a “non-blocked” generic product

What to map for financial trajectory

• Filing dates of any ANDAs referencing IMVEXXY
• Case numbers, status, and whether remedies included launch delays
• Whether settlements include exclusivity transfers (rare) or timeline-specific restrictions

What FDA regulatory milestones shape IMVEXXY uptake and competitive entry?

IMVEXXY’s near-term sales trajectory depends on continued clinical confidence and reliable supply, but competitive entry is driven by:

• ANDA approval timing
• Labeling and formulation equivalence
• REMS-like requirements (if any) and distribution controls
• Pharmacovigilance outcomes influencing payer comfort

Uptake milestones

• Initial adoption in women’s health practices
• Specialty pharmacy vs retail distribution efficiency
• Treatment persistence and switching patterns from creams/tablets

How does IMVEXXY financial performance compare with other local estrogen products?

Relative performance is driven by:

• Net price positioning after discounts
• Patient persistence (insert usability vs cream dosing)
• Formulary tier placement and step edit patterns

Competitive comparison framework

• Category-level growth: GSM awareness and prescribing
• Share sensitivity: shift in prescription preference among local estrogen delivery systems
• Brand survival: whether IMVEXXY sustains premium differentiation after generic penetration

What generic entry risks exist for IMVEXXY, and how would launch scenarios impact revenue?

Generic exposure risk is dominated by:

• How quickly ANDA approvals can be converted into market reality
• Pharmacy substitutability (including payer-directed substitution)
• Whether the generic is priced aggressively enough to win switching

Launch scenario mechanics

• “Slow adoption” scenario: generics receive coverage but patient persistence to IMVEXXY stays high
• “Fast switch” scenario: IMVEXXY loses preferred tier and prescribers switch quickly after patient education and pharmacy formulary prompts
• “Design-around” scenario: generic with label carve-outs or dosing differences limits direct interchange and delays share loss

Revenue impact levers for IMVEXXY

• Net price erosion (rebate and contract renegotiations)
• Prescription share loss
• Margin pressure from maintaining commercial support despite declining volume

What commercialization and supply-chain risks could change IMVEXXY’s financial trajectory?

Local estrogen product performance can change quickly with:

• Manufacturing interruptions or scale-up constraints affecting allocation
• Quality system issues that force recalls or temporary distribution holds
• Supply normalization that either unlocks or constrains prescribing

Key takeaways

• IMVEXXY’s financial trajectory depends on formulary access and net pricing versus local estrogen substitutes, especially generics.
• Exclusivity and Orange Book patent listings are the principal determinants of generic timing and revenue step-down risk.
• Revenue inflections are most likely around Orange Book patent expiry windows, ANDA/PAR4 litigation outcomes, and settlement-driven launch delays.
• Short-term sales durability requires sustained payer preference and high patient persistence relative to tablets/creams/rings.

FAQs

1) What is IMVEXXY’s typical payer coverage strategy in GSM dyspareunia?
Coverage typically follows women’s health formulary rules that favor lower-cost local estradiol options, with exceptions driven by patient preference or intolerance to alternatives.

2) How do PBM rebates influence IMVEXXY net sales versus list price?
Rebates and contract terms determine net price and can either cushion demand during competitive pressure or accelerate revenue decline if coverage is lost.

3) What are the highest-risk times for IMVEXXY generic entry?
Risk concentrates in periods after expiration of Orange Book listed patents that block ANDAs and any associated exclusivity windows.

4) Does IMVEXXY face biosimilar competition?
IMVEXXY is not a biologic product in the typical biosimilar sense; competition is expected from ANDA-style generics of the small-molecule/local estradiol formulation.

5) What portfolio actions would most affect IMVEXXY revenue resilience?
Formulary positioning, contract renegotiations tied to net price, and litigation strategy against ANDA/PAR4 challenges drive the most visible revenue outcomes.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drug Trials Snapshots: IMVEXXY (estradiol vaginal insert). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots

DrugChatter Q&A for IMVEXXY

When will imvexxy come off patent?
Is imvexxy available in the uk?
Imvexxy without insurance?
Does imvexxy have a generic?
Imvexxy generic availability 2026?